Indication intelligence, analysis and sector perception

Ionis Pharmaceuticals (IONS) proposed $500 million private placement of Convertible Senior Notes

April 6, 2021 6:15pm

Closed up +$0.41 or +0.88% to $47.25

With a negative -$2.45 or -5.19% aftermarket indication to $44.80

IONS intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2026 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

Ionis also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $75 million principal amount of notes.

Stats:

52-week’s change: -6.45%

52-week low of $41.42 and a high of $64.37

Cash position: $1.9 billion

Total cash per share: $13.48

Float: 133.93 million shares

Short percentage (%) of float: 7.24%

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

ago
RegMed Investors’ (RMi) pre-open: lack of expectation as depreciated share pricing realities set-in

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.